Survey results
| N (%) | |
| Age (years) | |
| <30 | 48 (13.9) |
| 30–60 | 227 (65.8) |
| >60 | 70 (20.3) |
| Female | 311 (90.2) |
| Diseases | |
| Rheumatoid arthritis | 177 (51.3) |
| Systemic lupus erythematosus | 86 (24.9) |
| Primary Sjögren’s syndrome | 19 (5.5) |
| Axial spondyloarthritis | 14(4) |
| Psoriatic arthritis | 10 (2.9) |
| Inflammatory myopathies | 8 (2.3) |
| Scleroderma | 8 (2.3) |
| Vasculitis | 5 (1.5) |
| Other* | 18 (5.2) |
| Indicated treatment | |
| Synthetic DMARDs | 195 (56.5) |
| Biologic and target DMARDs | 25 (7.2) |
| Combined therapy (biologic and synthetic) DMARDs | 27 (7.8) |
| Chloroquine, hydroxychloroquine | 90(26) |
| Glucocorticoids | 139 (40.3) |
| NAIDs | 16 (4.6) |
| Behaviours answers | |
| Without changes in their indicated medication | 286 (82.9) |
| Without changes in their indicated medication but thinking of suspending | 7 (2) |
| Change in their medication (dose reduction, periodicity decrease or application delay) | 22 (6.4) |
| Suspension of the indicated medication | 17(5) |
| Suspension of the indicated medication and restart before the survey | 13 (3.7) |
| Changed or suspended treatment | |
| Synthetic DMARDs | 15 (28.8) |
| Biologic and target DMARDs | 8 (15.3) |
| Combined therapy (biologic and synthetic) DMARDs | 4 (7.7) |
| Chloroquine, hydroxychloroquine | 25 (48.1) |
| Glucocorticoids | 10 (19.2) |
| NAIDs | 1 (1.2) |
| Reasons for changes or suspension of their medication | |
| Lack of availability | 25 (48.1) |
| Fear of getting sick from COVID-19 | 13(25) |
| Indication of the rheumatologist | 4 (7.7) |
| Indication of other clinicians | 3 (5.8) |
| Economic reason | 2 (3.8) |
| Other | 5 (9.6) |
Synthetic DMARDs: methotretaxe, leflunomide, sulfasalazine, mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus. Biologic and target DMARDs: certolizumab, adalimumab, golimumab, rituximab, tocilizumab, belimumab, abatacept, baricitinib, tofacitinib.
*Other: juvenile idiopathic arthritis, mixed connective tissue disease, undifferentiated connective tissue disease, Still disease, primary antiphospholipid syndrome.
DMARDs, disease-modifying antirheumatic drugs; NAIDs, non-steroidal anti-inflammatory drugs.